Zusammenfassung
Hintergrund
Lymphome bei Kindern und Adoleszenten unterscheiden sich von denen des Erwachsenenalters in relativer Häufigkeit und Vielfältigkeit. Zudem werden Patient*innen jungen Alters nach spezifischen Standards pädiatrischer Lymphomstudiengruppen versorgt.
Ziel der Arbeit
Darstellung diagnostisch und klinisch relevanter Lymphome bei Kindern und Adoleszenten.
Material und Methoden
Eine selektive Literaturrecherche (http://www.ncbi.nlm.nih.gov) wurde mit den praktischen Erfahrungen der Autor*innen aus der klinisch-pathologischen Diagnostik kombiniert.
Ergebnisse
Kinder und Jugendliche leiden sehr viel häufiger an aggressiven Lymphomen und Precursor-Zell-Lymphomen als Erwachsene. Anders als bei erwachsenen Patient*innen werden Burkitt-Lymphome und diffuse großzellige B‑Zell-Lymphome nicht grundsätzlich unterschiedlich behandelt. Kürzlich beschriebene Entitäten, die besonders häufig bei jungen Patient*innen auftreten, sind das high-grade B‑Zell-Lymphom mit 11q-Aberrationen und das großzellige B‑Zell-Lymphom mit Translokationen von IRF4.
Schlussfolgerung
Lymphomdiagnostik bei Kindern und Adoleszenten ist vom besonderen Spektrum der Erkrankungen geprägt, das in diesem Alter auftritt. Spezielles Wissen über die klinische Relevanz der Diagnosen im Kindesalter ist hilfreich, um mit wenigen Untersuchungen schnell eine therapeutische Weichenstellung zu ermöglichen.
Abstract
Background
Lymphomas in children and adolescents differ from adulthood in relative frequency and variety of entities. In addition, young patients are cared for according to the specific standards of pediatric lymphoma study groups.
Objective
To present lymphomas of diagnostic and clinical relevance in the pediatric and adolescent group.
Material and methods
Selective literature research (http://www.ncbi.nlm.nih.gov) was combined with clinico-pathological experience of the authors.
Results
Children and adolescents are much more likely to suffer from aggressive and precursor cell lymphoma than is the case in adulthood. Unlike adult patients, Burkitt lymphomas and diffuse large B‑cell lymphomas are not treated fundamentally differently. Entities that have been described relatively recently and are particularly common in young patients are high-grade B‑cell lymphoma with 11q aberrations and large-cell B‑cell lymphoma with IRF4 translocations.
Conclusion
Lymphoma diagnosis in children and adolescents is characterized by the particular spectrum of diseases that occur at this age. Special knowledge about the clinical relevance of the diagnoses in childhood is helpful in order to enable rapid clinical decision making.
Literatur
Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720–1748
Attarbaschi A, Abla O, Arias Padilla L et al (2020) Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T‑cell lymphoma. Pediatr Blood Cancer 67:e28416
Attarbaschi A, Beishuizen A, Mann G et al (2013) Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “watch and wait” strategy after complete resection. Ann Hematol 1(1):1537–1541. https://doi.org/10.1007/s00277-013-1785-2
Au-Yeung RKHK (2019) Features of Pediatric B‑lymphoblastic lymphoma with KMT2A rearrangements in the German NHL-BFM Group. In: The 108th Annual Meeting of the Japanese Society of Pathology. Proceedings of the Japanese Society of Pathology Tokyo, S 420
Au-Yeung RKH, Arias Padilla L, Zimmermann M et al (2020) Experience with provisional WHO-entities large B‑cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group. Br J Haematol. https://doi.org/10.1111/bjh.16578
Beishuizen A, Mellgren K, Andrés M et al (2023) Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma. Lancet Haematol 10:e213–e224
Burkhardt B, Michgehl U, Rohde J et al (2022) Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun 13:3881
Burkhardt B, Zimmermann M, Oschlies I et al (2005) The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131:39–49
Jaffe E, H H, S H et al (2001) Pathology and genetics of tumours of haematopoetic and lymphoid tissues. IARC Press, Lyon, France
Klapper W, Kreuz M, Kohler CW et al (2012) Patient age at diagnosis is associated with the molecular characteristics of diffuse large B‑cell lymphoma. Blood 119:1882–1887
Kontny U, Oschlies I, Woessmann W et al (2015) Non-anaplastic peripheral T‑cell lymphoma in children and adolescents—a retrospective analysis of the NHL-BFM study group. Br J Haematol 168:835–844
Lamant L, Mccarthy K, D’amore E et al (2011) Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol 29:4669–4676
Laurent C, Cook JR, Yoshino T et al (2023) Follicular lymphoma and marginal zone lymphoma: how many diseases? Virchows Arch 482:149–162
Makarova O, Oschlies I, Muller S et al (2018) Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma. Br J Haematol 182:735–739
Mauz-Körholz C, Lange T, Hasenclever D et al (2015) Pediatric nodular lymphocyte-predominant Hodgkin Lymphoma: treatment recommendations of the GPOH-HD study group. Klin Padiatr 227:314–321
Mauz-Körholz C, Metzger ML, Kelly KM et al (2015) Pediatric Hodgkin Lymphoma. J Clin Oncol 33:2975–2985
Minard-Colin V, Aupérin A, Pillon M et al (2020) Rituximab for High-Risk, Mature B‑Cell Non-Hodgkin’s Lymphoma in Children. N Engl J Med 382:2207–2219
Möker P, Zur Stadt U, Zimmermann M et al (2022) Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia. Leukemia 36:2343–2346
Mottok A, Hung SS, Chavez EA et al (2019) Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B‑cell lymphoma. Blood 134:802–813
Oschlies I, Burkhardt B, Chassagne-Clement C et al (2011) Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol 35:836–844
Oschlies I, Salaverria I, Mahn F et al (2009) Pediatric follicular lymphoma—a clinico-pathological study of a population-based series of patients treated within the NHL-BFM (Berlin-Frankfurt-Munster) multicenter trials. Haematologica 95(2):253–259. https://doi.org/10.3324/haematol.2009.013177
Richter J, John K, Staiger AM et al (2022) Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. Br J Haematol 196:681–689
Salaverria I, Martin-Guerrero I, Wagener R et al (2014) A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B‑cell lymphomas resembling Burkitt lymphoma. Blood 123:1187–1198
Salaverria I, Philipp C, Oschlies I et al (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B‑cell lymphoma affecting predominantly children and young adults. Blood 118:139–147
Salmeron-Villalobos J, Egan C, Borgmann V et al (2022) A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile. Blood Adv 6:4661–4674
Sarkozy C, Chong L, Takata K et al (2020) Gene expression profiling of gray zone lymphoma. Blood Adv 4:2523–2535
Sarkozy C, Copie-Bergman C, Damotte D et al (2019) Gray-zone Lymphoma between cHL and large B‑cell Lymphoma: a Histopathologic series from the LYSA. Am J Surg Pathol 43:341–351
Sarkozy C, Hung SS, Chavez EA et al (2021) Mutational landscape of gray zone lymphoma. Blood 137:1765–1776
Szczepanowski M, Lange J, Kohler CW et al (2017) Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B‑cell lymphoma of children and adolescents. Br J Haematol 179:116–119
Thomas N, Dreval K, Gerhard DS et al (2023) Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood 141:904–916
Woessmann W, Lisfeld J, Burkhardt B (2013) Therapy in primary mediastinal B‑cell lymphoma. N Engl J Med 369:282
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
W. Klapper gibt an: Mein Universitätsklinikum erhält Forschungsförderung und Beratungshonorare von Roche, Amgen, Takeda, Janssen. Keine Mittel gehen privat zu meinen Händen und keine Mittel bzw. Tätigkeiten dafür haben inhaltlichen Bezug zu dem hier verfassten Manuskript.
Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Schwerpunktherausgeber
Christian Vokuhl, Bonn
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Klapper, W. Lymphome bei Kindern und Adoleszenten. Pathologie 44, 338–347 (2023). https://doi.org/10.1007/s00292-023-01216-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-023-01216-2
Schlüsselwörter
- Großzellig anaplastisches Lymphom
- Burkitt-Lymphom
- Diffuses großzelliges B‑Zell-Lymphom
- Hodgkin-Lymphom
- Epstein-Barr-Virus-Infektion